Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 12/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598706 | 0.85 | DRD2 (0.74) | DRD2OPRM1DRD3HTR7KCNH2 | |
| SCHEMBL7240053 | 0.84 | DRD2 (0.72) | DRD2OPRM1DRD3HTR7KCNH2 | |
| SCHEMBL3453730 | 0.84 | DRD2 (1.00) | DRD2OPRM1DRD3HTR7 | |
| SCHEMBL3187228 | 0.83 | DRD2 (0.67) | DRD2OPRM1DRD3HTR7KCNH2 | |
| SCHEMBL9723025 | 0.82 | DRD2 (0.68) | DRD2OPRM1DRD3HTR7 | |
| Hydrochloric Acid SCHEMBL3196389 | 0.82 | OPRM1 (0.65) | DRD2OPRM1DRD3HTR7KCNH2 | |
| SCHEMBL28662734 | 0.81 | DRD2 (0.83) | DRD2OPRM1DRD3HTR7KCNH2 | |
| SCHEMBL2388166 | 0.80 | DRD2 (0.71) | DRD2OPRM1DRD3HTR7 | |
| SCHEMBL1599712 | 0.80 | DRD2 (0.77) | DRD2OPRM1DRD3HTR7 | |
| SCHEMBL2466774 | 0.78 | OPRM1 (1.00) | DRD2OPRM1DRD3HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1483262-B1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| CN-1628114-A | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | DRD2 3105/4885OPRM1 1523/4885DRD3 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.